In Washington, on January 6, 2026, Donald Trump claimed to have obtained from Emmanuel Macron a price increase. This increase concerns medications in France, potentially up to 200%, according to his statements. He brandished the threat of 25% tariffs on medications. Paris denies this and recalls that these prices are regulated by health and budgetary procedures. Behind the scenes, it’s mainly a narrative tug-of-war aimed at the American public on an explosive topic: the cost of treatments.
A domestic political sequence exported to the diplomatic stage
On January 6, 2026, in Washington, Donald Trump, President of the United States, reiterated a story he had already delivered. At the end of December 2025, he mentioned a phone exchange with Emmanuel Macron, President of the French Republic. During this call, he allegedly forced Macron to accept a 200% increase in the price of medications in France.
On January 7, 2026, the Élysée issued a denial: no concession would have been granted and, above all, the setting of prices for reimbursable medications in France follows a regulatory framework. Beyond the denial, the episode highlights a very political use of the international stage: a technical subject turned into a demonstration of authority.
What Trump claims about medication prices – and what the Élysée denies
In his version, Donald Trump describes a conversation where he allegedly demanded that France significantly raise its prices — mentioning an increase of 200% or more — to "rebalance" a market he deems unfavorable to Americans. He often accompanies this type of narrative with a commercial threat: tariffs of up to 25% on French or European products.
This narrative fits into a consistent political line. Trump claims that the United States pays "much more" for their medications than in Europe. As a result, they would indirectly finance foreign health systems. The logic he proposes is simple, almost mechanical: if others pay more, laboratories would have less reason to compensate their margins in the United States.
On the French side, the Élysée denies any concession on medication prices and refers to the institutional framework. Even if a phone exchange took place, the presidency alone cannot decree an increase. Indeed, a generalized price increase in pharmacies requires other interventions. The French response has been all the more cautious because the diplomatic agenda between Paris and Washington remains busy, particularly concerning European security issues.
Regulation of medication prices in France: who decides?
France distinguishes, schematically, two worlds.
On one hand, reimbursable medications (those covered by health insurance, fully or partially). Their price is regulated: it results from a process involving medical evaluation, economic negotiation, and then administrative decisions.
On the other hand, non-reimbursable medications. Their price is in principle free, which can lead to variations depending on points of sale and periods.
For reimbursable medications, the chain is structured:
- The Haute Autorité de santé (HAS) evaluates the medical interest and the place of the medication.
- The Comité économique des produits de santé (CEPS) negotiates the price, most often through agreements, with companies. This is done within a framework of public guidelines.
- The competent ministers then make decisions according to the prescribed procedures.
In other words, even if the executive sets guidelines, the final price is the product of a broader mechanism. This mechanism is based on evaluations and negotiations. It is this framework that the Élysée highlights to downplay the significance of a narrative presented as a personal "agreement."
For patients, this architecture has a concrete effect: the price displayed in pharmacies is not just a "market" price. In reality, it is an element of balance between access to treatments, the sustainability of public spending, and the remuneration of innovation.
Medication prices in the United States: why they remain higher than in Europe
In the United States, the cost of prescription medications has fueled a cross-cutting debate for years. Indeed, it weighs on households, insurers, and public finances. In a USA–Europe medication price comparison, the American bill often appears higher, in a system where negotiations involve a multitude of actors (insurers, pharmacy networks, intermediaries), without a single "administered" price.
Since his return to power, Donald Trump has emphasized a guiding idea: to obtain, through coercion or new rules, a more favorable price level for American patients. In this logic, Europe is presented as a counter-model and sometimes as a "beneficiary" of lower prices. Consequently, this makes the subject politically effective, even if the real mechanisms are more complex.
Tariffs (25%) on medications: real leverage, uncertain outcome
The threat of 25% tariffs fits into a practice already observed under Trump’s mandates: using trade as a tool of political negotiation. Legally and economically, the United States can indeed impose tariffs on imports, including European ones.
But the effectiveness of the leverage is less evident than a slogan.
First, a tariff increase targets imported products; it does not automatically change administered prices in a foreign health system. In France, even if the executive decided to revise its strategy, it would involve technical and budgetary discussions. Moreover, these discussions would be accompanied by regulated decisions.
Finally, the pharmaceutical sector is particular. States wish to secure access to essential treatments and limit disruptions. A commercial confrontation, during a period of fragility in global production chains, can become politically risky. This includes risks for the one who initiates it.
A Trump–Macron relationship often personified
The episode fits into an already very personified relationship. Between Trump and Macron, diplomacy has often been reduced to scenes and symbols: scrutinized gestures, repeated phrases, narratives of victories or frustrations.
The scenario of a "won" call fits this grammar: it shows a leader who claims to be able to achieve, alone, a spectacular result. Paris, on the other hand, refers to the institutional and avoids escalation, at the risk of leaving the media space to the loudest narrator.
What is verifiable, what is not
Three elements can be established without difficulty.
- Donald Trump did indeed make public statements describing an exchange with Emmanuel Macron. He mentioned a very strong increase in medication prices.
- The Élysée did indeed issue a denial, recalling that the French president does not set medication prices alone.
- The issue of medication prices is a politically inflammatory topic in the United States. Indeed, the comparison with Europe regularly fuels promises and controversies.
However, the precise reality of the exchange remains not publicly established. The exact content of the call and the tone remain unknown. Moreover, the existence of an "agreement" is not confirmed. By nature, a bilateral conversation cannot be proven by an on-stage imitation. And no change in French doctrine has been announced in the aftermath.
What are the concrete stakes for France and the pharmaceutical industry
In the short term, the sequence does not mechanically announce a price increase in France. But it reminds that medication can become, on the American side, a tool of commercial pressure.
For the pharmaceutical industry, this means more uncertainty. Indeed, production, supply, and launch decisions are made over several years. Moreover, tariff threats, even without immediate effects, weigh on calculations.
For the French state, the challenge is to maintain a stable line: ensuring access to treatments and controlling spending. Furthermore, it is about supporting health sovereignty without giving the impression of negotiating under an ultimatum. For patients, the point of attention remains clarity: a spectacular percentage does not alone indicate what is related to the face value, reimbursement, or out-of-pocket costs.
Practical references
- The prices of reimbursable medications are regulated and can be consulted via the French public database.
- The reimbursement rate depends on the medical situation, the type of product, and the rules of health insurance.
- Significant price changes, in practice, go through administrative decisions, agreements, and budgetary arbitrations; they are not instantaneous.
A mostly rhetorical tug-of-war, without immediate effect
The Trump–Macron sequence on medication prices illustrates a classic tension: a technical, complex, and regulated subject becomes a tool of political communication, carried by a staging of personal victory. The Élysée’s denial recalls the reality of the French system: medication prices, especially reimbursable ones, are not decided at the scale of a tête-à-tête.
A lasting fact persists: in the United States, the battle over the cost of medications continues to fuel offensive strategies. These include commercial approaches, which may eventually weigh on transatlantic balances.